A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya (COV004)
Latest Information Update: 10 Dec 2020
At a glance
- Drugs AZD 1222 (Primary) ; Rabies vaccine
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 30 Nov 2020 Status changed from not yet recruiting to recruiting.
- 05 Oct 2020 Planned initiation date changed from 31 May 2020 to 1 Oct 2020.
- 31 Jul 2020 New trial record